Coordinated ASBT and EGFR Mechanisms for Optimized Liraglutide Nanoformulation Absorption in the GI Tract

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2024 Mar 28

PMID 38544951

Authors

Seho Kweon

Seong Jin Park

Ha Kyeong Lee

Seo Hee Kang

Kwan-Young Chang

Jeong Uk Choi

Jooho Park

Jung-Hyun Shim

Jin Woo Park

Youngro Byun

Affiliations

Soon will be listed here.

Abstract

Background: For maintenance therapy in type 2 diabetes, glucagon-like peptide-1 agonist (GLP-1A), which exhibits low cardiovascular risk and high efficacy, is a promising peptide therapeutic. However, developing an oral GLP-1A presents challenges due to the analog's poor cellular permeability and gastrointestinal (GI) stability.

Methods: To mitigate such limitations, an oral nanoformulation of liraglutide (LG) was designed and achieved by combining LG with bile acid derivatives using the nanoprecipitation method. This strategy allowed the bile acid moieties to localize at the nanoparticle surface, enhancing the binding affinity for apical sodium-dependent bile acid transporter (ASBT) and improving GI stability. The in vitro characteristics, cellular permeability, and absorption mechanisms of the LG nanoformulation (LG/TD-NF) were thoroughly investigated. Furthermore, the in vivo oral absorption in rats and the glucose-lowering effects in a diabetic () mouse model were evaluated.

Results: The LG/TD-NF produced neutral nanoparticles with a diameter of 58.7 ± 4.3 nm and a zeta potential of 4.9 ± 0.4 mV. Notably, when exposed to simulated gastric fluid, 65.7 ± 3.6% of the LG/TD-NF remained stable over 120 min, while free LG was fully degraded. Relative to unformulated LG, the Caco-2 cellular permeability of the nanoformulation improved, measuring 10.9 ± 2.1 (× 10 cm/s). The absorption mechanism prominently featured endocytosis simultaneously mediated by both ASBT and epidermal growth factor receptor (EGFR). The oral bioavailability of the LG/TD-NF was determined to be 3.62% at a dosage of 10 mg/kg, which is 45.3 times greater than that of free LG. In a diabetes model, LG/TD-NF at 10 mg/kg/day exhibited commendable glucose sensitivity and reduced HbA1c levels by 4.13% within 28 days, similar to that of subcutaneously administered LG at a dosage of 0.1 mg/kg/day.

Conclusion: The oral LG/TD-NF promotes ASBT/EGFR-mediated transcytosis and assures cellular permeability within the GI tract. This method holds promise for the development of oral GLP-1A peptides as an alternative to injections, potentially enhancing patient adherence to maintenance therapy.

References

Aguilar R, Wendland B . Endocytosis of membrane receptors: two pathways are better than one. Proc Natl Acad Sci U S A. 2005; 102(8):2679-80. PMC: 549498. DOI: 10.1073/pnas.0500213102. View

Wang Y, Yamaguchi H, Hsu J, Hung M . Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene. 2010; 29(28):3997-4006. PMC: 2904849. DOI: 10.1038/onc.2010.157. View

Xu Q, Ensign L, Boylan N, Schon A, Gong X, Yang J . Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo. ACS Nano. 2015; 9(9):9217-27. PMC: 4890729. DOI: 10.1021/acsnano.5b03876. View

Liao R, Pon J, Chungyoun M, Nance E . Enzymatic protection and biocompatibility screening of enzyme-loaded polymeric nanoparticles for neurotherapeutic applications. Biomaterials. 2020; 257:120238. PMC: 7442737. DOI: 10.1016/j.biomaterials.2020.120238. View

Boye K, Ross M, Mody R, Konig M, Gelhorn H . Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study. Diabetes Obes Metab. 2020; 23(2):508-519. PMC: 7839441. DOI: 10.1111/dom.14244. View

Fan W, Wei Q, Xiang J, Tang Y, Zhou Q, Geng Y . Mucus Penetrating and Cell-Binding Polyzwitterionic Micelles as Potent Oral Nanomedicine for Cancer Drug Delivery. Adv Mater. 2022; 34(16):e2109189. DOI: 10.1002/adma.202109189. View

Jha S, Young Chung J, Pangeni R, Choi H, Subedi L, Kweon S . Enhanced antitumor efficacy of bile acid-lipid complex-anchored docetaxel nanoemulsion via oral metronomic scheduling. J Control Release. 2020; 328:368-394. DOI: 10.1016/j.jconrel.2020.08.067. View

Ni Y, Lempp F, Mehrle S, Nkongolo S, Kaufman C, Falth M . Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2013; 146(4):1070-83. DOI: 10.1053/j.gastro.2013.12.024. View

Al-Hilal T, Chung S, Alam F, Park J, Lee K, Jeon H . Functional transformations of bile acid transporters induced by high-affinity macromolecules. Sci Rep. 2014; 4:4163. PMC: 3933907. DOI: 10.1038/srep04163. View

10.

Dalsgaard N, Vilsboll T, Knop F . Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. Diabetes Obes Metab. 2017; 20(3):508-519. PMC: 5836903. DOI: 10.1111/dom.13128. View

11.

Zhang X, Cheng H, Dong W, Zhang M, Liu Q, Wang X . Design and intestinal mucus penetration mechanism of core-shell nanocomplex. J Control Release. 2018; 272:29-38. DOI: 10.1016/j.jconrel.2017.12.034. View

12.

Jiang L, Wang T, Wang Y, Wang Z, Bai Y . Co-disposition of chitosan nanoparticles by multi types of hepatic cells and their subsequent biological elimination: the mechanism and kinetic studies at the cellular and animal levels. Int J Nanomedicine. 2019; 14:6035-6060. PMC: 6681437. DOI: 10.2147/IJN.S208496. View

13.

Deng F, Kim K, Moon J, Bae Y . Bile Acid Conjugation on Solid Nanoparticles Enhances ASBT-Mediated Endocytosis and Chylomicron Pathway but Weakens the Transcytosis by Inducing Transport Flow in a Cellular Negative Feedback Loop. Adv Sci (Weinh). 2022; 9(21):e2201414. PMC: 9313510. DOI: 10.1002/advs.202201414. View

14.

Deng F, Bae Y . Lipid raft-mediated and upregulated coordination pathways assist transport of glycocholic acid-modified nanoparticle in a human breast cancer cell line of SK-BR-3. Int J Pharm. 2022; 617:121589. PMC: 8996487. DOI: 10.1016/j.ijpharm.2022.121589. View

15.

Deng F, Bae Y . Bile acid transporter-mediated oral drug delivery. J Control Release. 2020; 327:100-116. PMC: 7606772. DOI: 10.1016/j.jconrel.2020.07.034. View

16.

Park J, Choi J, Kim K, Byun Y . Bile acid transporter mediated endocytosis of oral bile acid conjugated nanocomplex. Biomaterials. 2017; 147:145-154. DOI: 10.1016/j.biomaterials.2017.09.022. View

17.

Kullak-Ublick G, Glasa J, Boker C, Oswald M, Grutzner U, Hagenbuch B . Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology. 1997; 113(4):1295-305. DOI: 10.1053/gast.1997.v113.pm9322525. View

18.

Muttenthaler M, King G, Adams D, Alewood P . Trends in peptide drug discovery. Nat Rev Drug Discov. 2021; 20(4):309-325. DOI: 10.1038/s41573-020-00135-8. View

19.

Patching S . Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery. Biochim Biophys Acta. 2013; 1838(1 Pt A):43-55. DOI: 10.1016/j.bbamem.2013.04.028. View

20.

Kim K, Suzuki K, Cho H, Youn Y, Bae Y . Oral Nanoparticles Exhibit Specific High-Efficiency Intestinal Uptake and Lymphatic Transport. ACS Nano. 2018; 12(9):8893-8900. PMC: 6377080. DOI: 10.1021/acsnano.8b04315. View